Status: Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Participants needed: 116
Trial details
Phase: Phase 1Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: May 5, 2026Locations: 6
Eligibility criteria
Age ≥ 18 years old [+4]
Absolute neutrophil count (ANC) < 1.0 x 109/L, hemoglobin < 9 g/dL, or platelet... [+6]